<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="604">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02554812</url>
  </required_header>
  <id_info>
    <org_study_id>B9991004</org_study_id>
    <secondary_id>2015-002552-27</secondary_id>
    <secondary_id>JAVELIN MEDLEY</secondary_id>
    <nct_id>NCT02554812</nct_id>
  </id_info>
  <brief_title>A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)</brief_title>
  <official_title>A Phase 1b/2 Open-Label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics,
      pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in
      combination with other cancer immunotherapies in patients with locally advanced or
      metastatic solid tumors. The primary purpose is to assess the safety and early signs of
      efficacy of various avelumab combinations with other cancer immunotherapies, optimizing
      dosing regimens as appropriate, in a limited series of indications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Dose-Limiting Toxicities (DLT)</measure>
    <time_frame>First 8 weeks of treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>For Phase 1b: DLTs for Combination A (avelumab and PF-05082566) or Combination B (avelumab and PF-04518600) occurring during the first 8 weeks of treatment (first 2 cycles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response - Number of Participants With Objective Response</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>For Phase 2: Number of participants with objective response (ie, confirmed complete or partial response according to RECIST Version 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax defined as the maximum plasma concentration of avelumab (MSB0010718C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-05082566</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, and then on Day 1 of Cycles 3, 5, 8, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax defined as the maximum plasma concentration of PF-05082566</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough is defined as the trough plasma concentration at the end of an avelumab dosage interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of PF-05082566</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, and then on Day 1 of Cycles 3, 5, 8, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough is defined as the trough plasma concentration at the end of a PF-05082566 dosage interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of avelumab (MSB0010718C)</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity assessment of avelumab (MSB0010718C).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of PF-05082566</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 3, 5, 8, and 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity assessment of PF-05082566.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tumor Response (TTR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to Tumor Response (TTR) is defined for patients with confirmed objective response (CR or PR) as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the first documentation of objective tumor response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of Response (DR) is defined for patients with confirmed objective response (CR or PR) as the time from the first documentation of objective tumor response to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-Free Survival (PFS) is defined as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the date of disease progression by RECIST v1.1 or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline up to approximately 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall Survival (OS) is defined as the time from the date of randomization (NSCLC) or date of first dose of study treatment (melanoma and SCCHN) to the date of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor tissue biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tumor tissue biomarkers, including, but not limited to, PD-L1 expression and tumor infiltrating CD8+ T lymphocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of PF-04518600</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax defined as the maximum plasma concentration of PF-04518600</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibody (ADA) levels of PF-04518600</measure>
    <time_frame>Pre-dose on Day 1 of Cycles 1, 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Immunogenicity assessment of PF-04518600.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough of PF-04518600</measure>
    <time_frame>Pre-dose and 1 hour post-dose on Days 1, 8, and 15 of Cycle 1, then on Day 1 of Cycles 2, 4, 6, and 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ctrough is defined as the trough plasma concentration at the end of a PF-04518600 dosage interval.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">317</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + PF-05082566 (Dose level 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + PF-05082566 (Dose level 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NSCLC patients treated with avelumab + PF-05082566 (Dose level 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Melanoma patients treated with avelumab + PF-05082566</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SCCHN patients treated with avelumab + PF-05082566</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TNBC patients treated with avelumab + PF-05082566</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04518600 + avelumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-04518600 + avelumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Anti-PD-L1 antibody given until disease progression.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_label>Cohort A6</arm_group_label>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05082566</intervention_name>
    <description>Anti-4-1BB antibody at 1 of 3 dose levels to optimize the combination with avelumab. Treatment with the combination of avelumab and PF-05082566 will continue until disease progression.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort A3</arm_group_label>
    <arm_group_label>Cohort A4</arm_group_label>
    <arm_group_label>Cohort A5</arm_group_label>
    <arm_group_label>Cohort A6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Dose escalation: PF-04518600 will be administered at increasing dose levels in combination with avelumab.</description>
    <arm_group_label>Combination B Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04518600</intervention_name>
    <description>Dose expansion: patients with selected tumor types (NSCLC, melanoma, SCCHN, CRC) will be treated with PF-04518600 in combination with avelumab.</description>
    <arm_group_label>Combination B Expansion Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological or cytological diagnosis of advanced/metastatic solid tumor. Combination
             A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for
             which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma,
             SCCHN, TNBC in any line of therapy. Combination B: Phase 1b, patients with advanced
             solid tumors that have progressed on standard therapy or for which no standard
             therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN in any
             line of therapy, or locally advanced/metastatic CRC progressed after 1 line of
             standard therapy. NSCLC patients in Phase 2 with tumor ALK or EGFR mutations must
             have received or been refractory/intolerant to standard therapy

          -  ECOG performance status 0 or 1

          -  Estimated life expectancy of at least 3 months

          -  Adequate bone marrow, renal, and liver function

          -  Resolved acute effects of prior therapy

          -  Negative serum pregnancy test at screening

          -  Male and female patients able to have children must agree to use 2 highly effective
             methods of contraception throughout the study and for at least 60 days after last
             dose

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or
             small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14
             days prior to study entry.

          -  Current or prior use of immunosuppressive medication within 7 days prior to study
             entry

          -  Active autoimmune disease requiring systemic steroids or immunosuppressive agents
             within 7 days prior to study entry

          -  Known prior or suspected hypersensitivity to investigational products

          -  Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry

          -  Patients with known symptomatic brain metastases requiring steroids

          -  Previous high-dose chemotherapy requiring stem cell rescue

          -  Prior allogeneic stem cell transplant or organ graft

          -  Any of the following within 6 months prior to study entry: myocardial infarction,
             uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
             heart failure, cerebrovascular accident, or transient ischemic attack

          -  Symptomatic pulmonary embolism within 6 months prior to study entry

          -  Known HIV or AIDS-related illness

          -  Active infection requiring systemic therapy

          -  Positive HBV or HCV test indicating acute or chronic infection

          -  Administration of a live vaccine within 4 weeks prior to study entry

          -  Diagnosis of other malignancy within 5 years, except for adequately treated basal
             cell or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or
             low-grade (Gleason â‰¤6) prostate cancer

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to study entry and/or during study participation

          -  Persisting toxicity related to prior therapy &gt;Grade 1

          -  Other severe acute or chronic medical condition, including colitis, inflammatory
             bowel disease, and pneumonitis or psychiatric condition, recent or active suicidal
             ideation or behavior, or end stage renal disease on hemodialysis, or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational products administration or may interfere with the interpretation of
             results and, in the judgment of the Investigator, would make the patient
             inappropriate study entry
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center La Jolla (Thornton Hospital)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical Research Unit (Adminstration Office)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology-Oncology Infusion Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego Medical Center - Hillcrest</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Comprehensive Cancer Center - Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Clinton</city>
        <state>North Carolina</state>
        <zip>28328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Wilson</city>
        <state>North Carolina</state>
        <zip>27893</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute / Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991004&amp;StudyName=A%20Phase%201b%2F2%20Open-label%20Study%20To%20Evaluate%20Safety%2C%20Clinical%20Activity%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Avelumab%2A%20%28msb0010718c%29%20In%20Combination%20With%20Other%20Cancer%20Immunotherapies%20In%20Patients%20With%20Advanced%20Malignancies</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 10, 2016</lastchanged_date>
  <firstreceived_date>September 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti PD-L1</keyword>
  <keyword>anti 4-1BB</keyword>
  <keyword>Non-small cell lung cancer (NSCLC)</keyword>
  <keyword>melanoma</keyword>
  <keyword>squamous cell carcinoma of head and neck (SCCHN)</keyword>
  <keyword>triple negative breast cancer (TNBC)</keyword>
  <keyword>colorectal cancer (CRC)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
